Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Biologic drugs (1)
- Biologics Price Competition and Innovation Act (1)
- Biology (1)
- Decision making (1)
- Drugs (1)
-
- Electromagnetic spectrum (1)
- Equivalence (1)
- Federal Communications Commission (1)
- Food and Drug Administration (1)
- Internet (1)
- Law reform (1)
- Mobile devices (1)
- Molecular structure (1)
- Obviousness (1)
- Patent law (1)
- Patentability (1)
- Pharmaceuticals (1)
- Similarity (1)
- Spectrum auctions (1)
- Wireless (1)
Articles 1 - 2 of 2
Full-Text Articles in Law
Wireless Localism: Beyond The Shroud Of Objectivity In Federal Spectrum Administration, Olivier Sylvain
Wireless Localism: Beyond The Shroud Of Objectivity In Federal Spectrum Administration, Olivier Sylvain
Michigan Telecommunications & Technology Law Review
Recent innovations in mobile wireless technology have instigated a debate between two camps of legal scholars about federal administration of the electromagnetic spectrum. The first camp argues that the Federal Communications Commission (“FCC”) should define spectrum use rights more clearly and give spectrum licensees broad property rights in frequencies. The second camp argues that, rather than award exclusive licenses to the highest bidder, the FCC ought to open much, if not most, of the spectrum to unlicensed use by smartphones and tablets equipped with the newest spectrum administration technology. First, this Article shows that both of these camps comprise a …
Interpreting Biological Similarity: Ongoing Challenges For Diverse Decision Makers, Sarah M. Cork
Interpreting Biological Similarity: Ongoing Challenges For Diverse Decision Makers, Sarah M. Cork
Michigan Telecommunications & Technology Law Review
Similarity is an elusive and complicated concept facing comparisons of biological molecules, as even minute changes to a molecule's structure can dramatically affect its function in the body. Yet the flood of biologic drugs on the market will increasingly force these similarity comparisons. These concerns are particularly relevant to two groups of drugs: families of biologic drugs that closely resemble each other in structure and function, here termed "similar-impact biologics," and the biosimilars, which are intended to closely approximate generic forms of biologic drugs. In bringing biologic drugs to the market, manufacturers are likely to face dual obstacles: FDA approval …